Recruitment

Recruitment Status
Recruiting
Estimated Enrollment
Same as current

Summary

Conditions
  • Atypical Chronic Myeloid Leukemia
  • Chronic Myelomonocytic Leukemia
  • Myelodysplastic Syndrome
  • Myelodysplastic/Myeloproliferative Overlapping Syndrome
  • Myeloproliferative Neoplasms
Type
Interventional
Phase
Phase 2
Design
Allocation: N/AIntervention Model: Single Group AssignmentIntervention Model Description: This is a prospective, single center, phase II pilot treatment-allocation study at MSK for older patients considering allogeneic hematopoietic cell transplantation.Masking: None (Open Label)Primary Purpose: Treatment

Participation Requirements

Age
Between 60 years and 125 years
Gender
Both males and females

Description

This is a prospective, phase II study evaluating the efficacy of a risk-adapted, personalized allo-HCT strategy based on geriatric vulnerabilities identified by pre-transplant GA. The less vulnerable/fit older patients are recommended to receive MA conditioning and the more vulnerable older patients...

This is a prospective, phase II study evaluating the efficacy of a risk-adapted, personalized allo-HCT strategy based on geriatric vulnerabilities identified by pre-transplant GA. The less vulnerable/fit older patients are recommended to receive MA conditioning and the more vulnerable older patients are recommended to receive RIC/NMA conditioning. HCT-CI/Age ?4 AND no IADL impairment (less vulnerable/fit) -> MA regimen HCT-CI/Age >4 AND/OR any IADL impairment (more vulnerable) -> RIC/NMA regimen Chemotherapies: busulfan, fludarabine, melphalan, cyclophosphamide, thiotepa, clofarabine Radiation therapy: total body irradiation (TBI) Other therapy: anti-thymocyte globulin (ATG)

Tracking Information

NCT #
NCT04761770
Collaborators
Not Provided
Investigators
Principal Investigator: Richard J Lin, MD, PhD Memorial Sloan Kettering Cancer Center
About Us
Innovation
Privacy
Terms
Copyright
Get Well Soon © Copyright 2024